A Arcaro

Summary

Affiliation: University of Bern
Country: Switzerland

Publications

  1. ncbi request reprint Phosphatidylinositol 3-kinase isoforms as novel drug targets
    Karolina Błajecka
    University of Bern, Department of Clinical Research, Bern, Switzerland
    Curr Drug Targets 12:1056-81. 2011
  2. doi request reprint A sensitized RNA interference screen identifies a novel role for the PI3K p110γ isoform in medulloblastoma cell proliferation and chemoresistance
    Ana S Guerreiro
    Department of Oncology, University Children s Hospital, Zurich, Switzerland
    Mol Cancer Res 9:925-35. 2011
  3. pmc Involvement of autophagy in the response of tumor cells to PtdIns3K inhibitors: therapeutic implications
    Alexandre Arcaro
    Department of Clinical Research, University of Bern, Switzerland
    Autophagy 9:607-8. 2013
  4. ncbi request reprint Targeting PI3KC2β impairs proliferation and survival in acute leukemia, brain tumours and neuroendocrine tumours
    Danielle Boller
    Division of Clinical Chemistry and Biochemistry, University Children s Hospital Zurich, Zurich, Switzerland
    Anticancer Res 32:3015-27. 2012
  5. ncbi request reprint The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors
    K Holand
    University of Bern, Department of Clinical Research, Bern, Switzerland
    Curr Cancer Drug Targets 11:894-918. 2011
  6. ncbi request reprint Quassinoids: From traditional drugs to new cancer therapeutics
    G Fiaschetti
    Department of Oncology, University Children s Hospital, Zurich, Switzerland
    Curr Med Chem 18:316-28. 2011

Collaborators

  • Ana S Guerreiro
  • Danielle Boller
  • Sarah Fattet
  • Tarek Shalaby
  • Olivier Delattre
  • Michael A Grotzer
  • Karolina Błajecka
  • K Holand
  • G Fiaschetti
  • Olivier Spertini
  • Anelia Schweri-Olac
  • Hiroyuki Kaizawa
  • Angela De Laurentiis
  • Marin Marinov
  • Michael D Waterfield
  • Paul Depledge
  • Takahide Ohishi
  • Tomonobu Koizumi
  • Anthony Robson
  • Nahid Saghir
  • Kathrin T Doepfner
  • Karl Frei
  • Katrin Höland
  • Masahiko Hayakawa
  • Alexandra N Elsing
  • Abdullah Atamer
  • D Castelletti
  • F Salm
  • Dorota W Kulesza
  • M A Grotzer
  • Anna Borgström
  • Simone M Schoenwaelder
  • Shaun P Jackson
  • T Shalaby

Detail Information

Publications6

  1. ncbi request reprint Phosphatidylinositol 3-kinase isoforms as novel drug targets
    Karolina Błajecka
    University of Bern, Department of Clinical Research, Bern, Switzerland
    Curr Drug Targets 12:1056-81. 2011
    ..In addition, we will describe the drugs currently used in clinical trials, as well as promising emerging candidates...
  2. doi request reprint A sensitized RNA interference screen identifies a novel role for the PI3K p110γ isoform in medulloblastoma cell proliferation and chemoresistance
    Ana S Guerreiro
    Department of Oncology, University Children s Hospital, Zurich, Switzerland
    Mol Cancer Res 9:925-35. 2011
    ..Together, our data show that the p110γ phosphoinositide 3-kinase isoform is a novel target for combinatorial therapies in medulloblastoma...
  3. pmc Involvement of autophagy in the response of tumor cells to PtdIns3K inhibitors: therapeutic implications
    Alexandre Arcaro
    Department of Clinical Research, University of Bern, Switzerland
    Autophagy 9:607-8. 2013
    ..A better understanding of the contribution of autophagy to the action of PI3K inhibitors on tumors cells is important, since it may limit or enhance the action of these compounds, depending on the cellular context...
  4. ncbi request reprint Targeting PI3KC2β impairs proliferation and survival in acute leukemia, brain tumours and neuroendocrine tumours
    Danielle Boller
    Division of Clinical Chemistry and Biochemistry, University Children s Hospital Zurich, Zurich, Switzerland
    Anticancer Res 32:3015-27. 2012
    ..Eight human catalytic phosphoinositide 3-kinase (PI3K) isoforms exist which are subdivided into three classes. While class I isoforms have been well-studied in cancer, little is known about the functions of class II PI3Ks...
  5. ncbi request reprint The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors
    K Holand
    University of Bern, Department of Clinical Research, Bern, Switzerland
    Curr Cancer Drug Targets 11:894-918. 2011
    ....
  6. ncbi request reprint Quassinoids: From traditional drugs to new cancer therapeutics
    G Fiaschetti
    Department of Oncology, University Children s Hospital, Zurich, Switzerland
    Curr Med Chem 18:316-28. 2011
    ..Here, we review available knowledge of functionality and possible applications of quassinoids and quassinoid derivatives, spanning traditional use to the potential impact on modern medicine as cancer therapeutics...